Product Description
Piperacillin and tazobactam combination injection is used to treat bacterial infections in many different parts of the body (eg, stomach or bowel, lungs, skin, female reproductive organs). (Sourced from: https://www.mayoclinic.org/drugs-supplements/piperacillin-and-tazobactam-intravenous-route/description/drg-20072716)
Mechanisms of Action: LACTB Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Saudi Arabia | Serbia | South Africa | Spain | Sri Lanka | Sweden | Taiwan | Thailand | Tunisia | Turkey | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, Chile, China, Colombia, Croatia, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Mexico, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Russia, Saudi Arabia, Serbia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 9
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: COVID-19|Influenza, Human|Pneumonia
Phase 2: Bronchiectasis|Bronchitis, Chronic|Chronic Obstructive Pulmonary Disease|Coinfection|Community-Acquired Infections|Pyelonephritis|Respiratory Tract Infections|Urinary Tract Infections
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02735707 |
REMAP-CAP | P3 |
Recruiting |
Pneumonia|Influenza, Human|COVID-19 |
2026-02-01 |
2024-11-27 |
||
2022-501110-56-00 |
MK-7625A-036 | P1 |
Completed |
Pneumonia |
2024-05-30 |
88% |
2025-05-02 |
Treatments |
CTR20132852 |
CTR20132852 | P2 |
Active, not recruiting |
Pneumonia|Bronchitis, Chronic|Chronic Obstructive Pulmonary Disease|Respiratory Tract Infections|Pyelonephritis|Urinary Tract Infections|Coinfection|Community-Acquired Infections|Bronchiectasis |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20130987 |
CTR20130987 | P2 |
Recruiting |
Respiratory Tract Infections|Urinary Tract Infections |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20130999 |
CTR20130999 | P2 |
Active, not recruiting |
Unknown |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20132616 |
CTR20132616 | P2 |
Recruiting |
Urinary Tract Infections|Respiratory Tract Infections |
None |
2025-04-29 |
Treatments |
|
2021-006991-18 |
FRENCH24 ANIS | P3 |
Active, not recruiting |
Unknown |
2025-04-03 |
|||
NCT04223752 |
MK-7625A-036 | P1 |
Completed |
Pneumonia |
2024-09-14 |
88% |
2025-09-23 |
|
2018-000059-42 |
CEFTOREA | P3 |
Active, not recruiting |
Pneumonia |
2021-07-25 |
2022-03-13 |
Treatments |